<DOC>
	<DOCNO>NCT02606357</DOCNO>
	<brief_summary>Primary Objective : -To ass change glycosylated hemoglobin ( HbA1c ) uncontrolled Type 2 diabetes patient OAD agent Jordan 6 month treatment basal insulin ( Insulin glargine ) . Secondary Objectives : - To evaluate percentage patient achieve target HbA1c ˂7 % . - To evaluate change fast plasma glucose ( FPG ) . - To assess follow safety criterion : hypoglycemic event , body weight change , overall safety . - Describe titration process : change glargine insulin dose 3 month 6 month , change titration dos use ( ) , time reach control .</brief_summary>
	<brief_title>Treatment Type 2 Diabetes With Long Acting Basal Insulin Jordan</brief_title>
	<detailed_description>The total duration study period per patient 6 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patient ≥ 18 year old . Male Female . Type 2 diabetes patient . Uncontrolled previous therapy ( HbA1c &gt; 7 % ) , evident HbA1c test within last 1 month study entry . Insulin naïve patient : patient uncontrolled one maximum two line therapy include : monotherapy ( Metformin alone Oral AntiDiabetic agent ( OAD ) contraindicate intolerance ) and/or dual therapy ( OAD combination ) , maximum tolerate dose last 3 month . Signed informed consent . Signed informed consent . Exclusion criterion : Patient willing able perform selfmonitoring blood glucose . Patient willing able selftitrate insulin glargine physician 's guidance . Patient suitable participation accord specify approved Summary Product 's Characteristics accord medical clinical condition , judge Investigator . History impaired hepatic function define alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great three time upper limit normal , evident test do last 3 month . History impair renal function define serum creatinine &gt; 135 μmol/L ( &gt; 1.525 mg/dL ) men &gt; 110 μmol/L ( &gt; 1.243 mg/dL ) woman , evident test do last 3 month . Pregnant lactate woman ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method physician 's discretion ) . Treatment systemic corticosteroid within 3 month prior study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>